ANRO

NYSE 已收盘

Alto Neuroscience

26.51 USD
▲+0.60+2.32%
盘后 30.60 0.00%
2026-11-19
市值
$1.02B
市盈率
—
EPS
-2.36
股息率
—
52 周区间
12.51 – 37.48
成交量
573.02K
Beta
1.45
目标价
38.67
52W 低 12.5152W 高 37.48
价格走势

公司简介

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 pro...